Discovery/R&D

1. The Antibody Engine With Abpro's Chan Brothers 12/5/2022

   In an industry that takes new business naming conventions to etymological extremes, Abpro is a refreshingly clear exception. Brothers Ian Chan (CEO & Co-Founder) and Eugene Chan, M.D., (Chairman & Co-Founder) are antibody pros. The company's pipeline spans no fewer than 8 antibody candidates aimed at COVID-19, cancers including breast, gastric, and liver, and ophthalmologic indications DME and wet AMD. With a scientific advisory board led by Bob Langer, Ph.D. of Moderna fame and a new partnership with global powerhouse Celltrion worth a potential $1.75 billion, the company's on the move. On this episode of the Business of Biotech, the Chan brothers take us behind the scenes of Abpro's progress.

2. Lipid Nanoparticle Gene Coding With SalioGen Therapeutics' Ray Tabibiazar, M.D. 3/14/2022

   This episode of the Business of Biotech is fire. In fact, it's an interview with SalioGen Therapeutics Chairman and CEO Ray Tabibiazar, M.D.,, whose last name \_literally translates\_ to "Dr. Fire." Learn how he got that name, what's shaped his technology-agnostic philosophy on therapeutic development, the advantages of a genome engineering technology that leverages proprietary mammal-derived enzymes, rather than viruses, and how SalioGen is possibly carrying forth a pipeline that's 15 candidates deep and addressing eye, liver, heart, lung, bone marrow, and kidney diseases.

3. Innovating On The Frontier Of Radiopharmaceuticals With RadioMedix's Ebrahim Delpassand, M.D. 7/23/2025

   On this week's Business of Biotech episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing a radiopharmaceutical company focused on oncology.

4. Commensal Viral Vectors With Ring Therapeutics' Tuyen Ong, M.D. 4/12/2022

   When Tuyen Ong was a child, he and his family escaped Vietnam by boat in the dead of the night, bound for an Indonesian refugee camp. They spent a year in that camp before emigrating to the U.K., where Ong’s underprivileged adolescence found him growing up in the projects of London. Against the odds, Ong worked his way to UCL for an education that culminated with an M.D. Today, he’s CEO of Ring Therapeutics, a promising emerging biotech backed by Flagship Pioneering, the kingmaker behind the rise of Moderna. On this episode of the Business of Biotech, Ong shares on his challenging formative years, the unspoken love between a father and son, facing down racism as a poor Chinese kid in Vietnam and London, and how those experiences shape his leadership at Ring. Oh, and we talk about some pretty cool science, too.

5. The AAV Vector Challenge With Selecta's Dr. Carsten Brunn 1/12/2021

   The Business of Biotech kicks off our Cell & Gene Miniseries with Dr. Carsten Brunn, President & CEO at Selecta Biosciences. Guest host Erin Harris, chief editor at cellandgene.com, joins us for a discussion on Selecta's ImmTOR platform and how the company is addressing the immunogenicity of adeno-associated virus (AAV) vectors challenge faced by gene therapy companies.

6. Bio & The Business Of Aging with Life Biosciences' Jerry McLaughlin 9/7/2023

   Core to the clinical-stage biopharma Life Biosciences belief set is that "contrary to popular belief, aging is not caused by random wear and tear, but instead is caused by a discrete set of biological mechanisms that can be targeted therapeutically.”

7. Reprogramming Human Cells With bit.bio's Mark Kotter, M.D. 2/12/2024

   The concept of programmable biology is fueling a new breed of biotech, one that requires the marriage of computational and traditional science (and both computational and traditional scientists) on the entire journey from discovery to commercial. Bit.bio is exemplary of this new breed.

8. Plant-Based Biologics With iBio's Randy Maddux 2/14/2022

   iBio COO Randy Maddux walks us through the Bryan, Texas-based biopharma's attempt to turn the CHO cell biologic development paradigm on its ear with hydroponically-grown N. benthamiana. His company's FastPharming approach to protein production, he says, could be modularized to speed cycle times and dramatically reduce upstream costs at scales large and small. For its part, iBio is proving out the approach on a host of therapeutic and vaccine candidates for oncological, infectious, and fibrotic diseases.

9. Computational Drug Discovery With Gain Therapeutics' Matthias Alder 1/11/2023

   Gain Therapeutics' newly-appointed CEO Matthias Alder offers up a deep, yet abundantly clear explanation of how his company is applying compute power to speed up drug discovery. At Gain, computational models help researchers winnow down not just which molecules might have therapeutic effect, but also how adept those molecules will be at binding—and staying bound—to their target. It's not just theory, either. On this episode of the Business of Biotech, Alder shares on how the virtual successes seen on Gain's servers have translated in the wet lab, and how they've contributed to the company's fast-growing preclinical pipeline.

10. mRNA Upstarts With Radar Therapeutics' Sophia Lugo and Eerik Kaseniit, Ph.D. 8/25/2024

    Guest co-host Anna Rose Welch of Advancing RNA fame joins us on this week’s Business of Biotech podcast for a conversation with the leaders of RNA upstart Radar Therapeutics. The company’s co-founders, Eerik Kaseniit, Ph.D. (CSO & President) and Sophia Lugo (CEO), are making waves in the mRNA therapeutics space on the heels of the invention of a precision-expressed mRNA technology that laid bare the path to Radar’s inception.